Kidney disease drug trial seeks clues in urine
NCT ID NCT06435858
Summary
This study aims to understand how a drug called Empagliflozin affects the body's handling of important minerals like calcium and magnesium in people with an inherited form of kidney disease. Forty participants will take the drug or a placebo for two weeks while researchers measure changes in their urine and blood. The goal is to gather basic knowledge about how this drug works in this specific condition, not to treat symptoms or cure the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cantonal Hospital Graubuenden
RECRUITINGChur, Kanton Graubünden, 7000, Switzerland
Contact
Contact Email: •••••@•••••
-
University Hospital Zurich, Division of Nephrology
RECRUITINGZurich, Canton of Zurich, 8091, Switzerland
Contact
Conditions
Explore the condition pages connected to this study.